All In Biotech

Company

Pf Prism Cv

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

16

15 still marketed

Novel approvals

10

Approvals since 2021

12

Originals and new uses

Phase 3 trials

0

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Xeljanz new use Mar 6, 2026
  • Xeljanz new use Oct 16, 2025
  • Xeljanz new use Feb 21, 2025
  • Bosulif approved Priority reviewOrphanSep 26, 2023
  • Bosulif new use Priority reviewOrphanSep 26, 2023
  • Xalkori approved OrphanSep 7, 2023
  • Xalkori new use OrphanSep 7, 2023
  • Inlyta new use Sep 22, 2022
  • Xalkori new use Priority reviewOrphanJul 14, 2022
  • Xeljanz new use Dec 14, 2021

Drugs in development (0)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

No investigational drugs in Phase 2 or 3 trials under this sponsor name.

Recruiting Phase 3 trials

Largest first.

No recruiting Phase 3 trials under this sponsor name.

Marketed drugs (15)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.